CA
NZ
UK
AU
IND
US
Key HighlightsA published screener snapshot of November 5, 2026 showed Progyny (NASDAQ:PGNY) at USD 34.20, up 13.62% on the latest session, 22.01% over one week and 32.25% over one month, a topMid capperformer.Longer windows are also strong: 33.80% over three months and 46.22% over …
The catalyst here is anEarningsbeat on product sales paired with a guidance raise. Full year 2026 total revenue is now guided to USD 395 million to USD 405 million, and the nine month total of USD 282.5 million, up 37%, shows the run rate …
No single positive catalyst is clear, because the company cut its 2026 adjusted EBITDA outlook, excluding deferrals and recognitions, to USD 1.165 billion to USD 1.180 billion. General context: when expectations have already been lowered, a reported profit that beats a depressed bar, plus …
The rationale is a guidance raise from a stock priced for low expectations. Full year revenue is now USD 3.44 billion to USD 3.46 billion, from USD 3.40 billion to USD 3.45 billion. Adjusted EBITDA guidance rose to USD 615 million to USD 625 …
No single catalyst beyond the results was identified, and the reaction shows how a stock can rise on anEarningsmiss. Management said the fourth quarter should be the EBITDA trough, especially in phosphate, which lets investors price a recovery. Sulfur for the fourth quarter was …
The rationale is a strategicAcquisitionby a large software buyer that wants real-time customer engagement data for its AIMarketingtools. In a cash deal the target shares move toward the offer in one session, then trade at a discount that reflects the time to close and …
The catalyst is a settlement, not a trading fad. It ends all 6 pending suits (patent, trade secrets, contract and antitrust claims) and removes an open-ended injunction risk. Liquidia must remove the PH-ILD indication from its label and stop promoting it, but can keep …
The rationale is relief and low expectations, not a clean beat on sales. Same store sales fell 5.4%, but profit exceeded expectations in published coverage, and unit growth stayed strong. Guidance calls for a 2026 domestic same store sales decline of about 6.5% to …
The rationale is anEarningsbeat paired with a guidance raise. On August 6, 2026 management lifted full year growth guidance to about 20% from 14% to 16%, set an adjusted EBITDA margin range of 14.8% to 15.0% and added USD 100 million to the buyback. …
Key HighlightsViridian Therapeutics (NASDAQ:VRDN) traded at USD 28.66 in a published screener snapshot on November 5, 2026, up 50.84% in 1 month, 17.7% in 1 week, 24.72% in 3 months and 68.59% in 6 months.The latest session slipped 1.36%, and the stock sits in …
Please wait processing your request...